nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.12.2011 | Editorial Commentary

Imaging of neuroinflammation

verfasst von: Andrea Ciarmiello

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Excerpt

For those of us interested in molecular imaging of the major neurodegenerative disorders, the last decade has witnessed a marked advancement. From basic research to clinical studies, the field has evolved using multidisciplinary techniques and skills, leading to results of significant clinical interest. Reasoning on the role of inflammation in neurodegenerative disease, the recent paper by Santillo et al. [1] is an example of the breadth and depth of the evolving impact of molecular imaging on the field of neurodegeneration and stimulates a reflection on the state of the art of target-specific positron emission tomography (PET) probes of inflammation for brain imaging. …

Santillo AF, Gambini JP, Lannfelt L, Långström B, Ulla-Marja L, Kilander L, et al. In vivo imaging of astrocytosis in Alzheimer’s disease: an (11)C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging 2011. doi:10.1007/s00259-011-1895-9.

Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009;32:638–47. doi:10.1016/j.tins.2009.08.002.PubMedCrossRef

Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006;443:774–9. doi:10.1038/nature05290.PubMedCrossRef

Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008;60:430–40. doi:10.1016/j.neuron.2008.10.013.PubMedCrossRef

Jamin N, Neumann JM, Ostuni MA, Vu TK, Yao ZX, Murail S, et al. Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. Mol Endocrinol 2005;19:588–94. doi:10.1210/me.2004-0308.PubMedCrossRef

Lacapère JJ, Papadopoulos V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids 2003;68:569–85.PubMedCrossRef

Sutter AP, Maaser K, Höpfner M, Barthel B, Grabowski P, Faiss S, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer 2002;102:318–27. doi:10.1002/ijc.10724.PubMedCrossRef

Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358:461–7. doi:10.1016/S0140-6736(01)05625-2.PubMedCrossRef

Pappata S, Levasseur M, Gunn RN, Myers R, Crouzel C, Syrota A, et al. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology 2000;55:1052–4.PubMed

10.

Banati RB, Cagnin A, Brooks DJ, Gunn RN, Myers R, Jones T, et al. Long-term trans-synaptic glial responses in the human thalamus after peripheral nerve injury. Neuroreport 2001;12:3439–42.PubMedCrossRef

11.

Junck L, Olson JM, Ciliax BJ, Koeppe RA, Watkins GL, Jewett DM, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 1989;26:752–8. doi:10.1002/ana.410260611.PubMedCrossRef

12.

Goerres GW, Revesz T, Duncan J, Banati RB. Imaging cerebral vasculitis in refractory epilepsy using [(11)C](R)-PK11195 positron emission tomography. AJR Am J Roentgenol 2001;176:1016–8.PubMed

13.

Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp 2011;32:258–70. doi:10.1002/hbm.21008.PubMedCrossRef

14.

Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol 2004;56:894–7. doi:10.1002/ana.20332.PubMedCrossRef

15.

Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006;66:1638–43. doi:10.1212/01.wnl.0000222734.56412.17.PubMedCrossRef

16.

Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 2006;47:215–22.PubMed

17.

Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E, et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington’s disease. CNS Neurosci Ther 2009;15:1–11. doi:10.1111/j.1755-5949.2008.00068.x.PubMedCrossRef

18.

Takano A, Gulyás B, Varrone A, Karlsson P, Sjoholm N, Larsson S, et al. Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [(18)F]FEDAA1106: a human whole-body PET study. Eur J Nucl Med Mol Imaging 2011. doi:10.1007/s00259-011-1864-3.

19.

Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol 2006;147 Suppl 1:S287–96. doi:10.1038/sj.bjp.0706464.PubMed

20.

Saura J, Andrés N, Andrade C, Ojuel J, Eriksson K, Mahy N. Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol Aging 1997;18:497–507.PubMedCrossRef

21.

Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer’s disease: a biochemical and autoradiographical study. Neuroscience 1991;45:1–12.PubMedCrossRef

22.

Mann JJ, Kaplan RD, Bird ED. Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington’s disease compared to schizophrenics and controls. J Neural Transm 1986;65:277–83.PubMedCrossRef

23.

Ekblom J, Jossan SS, Oreland L, Walum E, Aquilonius SM. Reactive gliosis and monoamine oxidase B. J Neural Transm Suppl 1994;41:253–8.PubMed

24.

Ekblom J, Jossan SS, Bergström M, Oreland L, Walum E, Aquilonius SM. Monoamine oxidase-B in astrocytes. Glia 1993;8:122–32. doi:10.1002/glia.440080208.PubMedCrossRef

25.

Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 1987;235:481–5.PubMedCrossRef

26.

Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius SM, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci 2007;255:17–22. doi:10.1016/j.jns.2007.01.057.PubMedCrossRef

27.

Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergström M, et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging 2003;30:85–95. doi:10.1007/s00259-002-1008-x.PubMedCrossRef

28.

McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology 1992;42:447–9.PubMed

29.

Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C, et al. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 2008;436:196–200. doi:10.1016/j.neulet.2008.03.019.PubMedCrossRef

30.

Liu Z, Condello C, Schain A, Harb R, Grutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis. J Neurosci 2010;30:17091–101. doi:10.1523/JNEUROSCI.4403-10.2010.PubMedCrossRef

31.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718–25. doi:10.1212/01.wnl.0000261919.22630.ea.PubMedCrossRef

32.

Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med 2007;48:547–52.PubMedCrossRef

33.

Yen CK, Yano Y, Budinger TF, Friedland RP, Derenzo SE, Huesman RH, et al. Brain tumor evaluation using Rb-82 and positron emission tomography. J Nucl Med 1982;23:532–7.PubMed

34.

Iannotti F, Fieschi C, Alfano B, Picozzi P, Mansi L, Pozzilli C, et al. Simplified, noninvasive PET measurement of blood-brain barrier permeability. J Comput Assist Tomogr 1987;11:390–7.PubMedCrossRef

35.

Pozzilli C, Bernardi S, Mansi L, Picozzi P, Iannotti F, Alfano B, et al. Quantitative assessment of blood-brain barrier permeability in multiple sclerosis using 68-Ga-EDTA and positron emission tomography. J Neurol Neurosurg Psychiatry 1988;51:1058–62.PubMedCrossRef

36.

Carrió I. Key role of nuclear medicine in bringing imaging biomarkers into clinical practice. Eur J Nucl Med Mol Imaging 2009;36:1937–9. doi:10.1007/s00259-009-1318-3.PubMedCrossRef

37.

Stenström A, Arai Y, Oreland L. Intra- and extraneuronal monoamineoxidase-A and -B activities after central axotomy (hemisection) on rats. J Neural Transm 1985;61:105–13.PubMedCrossRef

Titel: Imaging of neuroinflammation
verfasst von: Andrea Ciarmiello
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1959-x

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Imaging of neuroinflammation

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2011

Erratum to: ApoSense: a novel technology for functional molecular imaging of cell death in models of acute renal tubular necrosis

Douglas Van Nostrand, Leonard Wartofsky, Gary Bloom, Kanchan P. Kulkarni (eds): Thyroid Cancer: a Guide for Patients

Certificate of Fellowship of the European Board of Nuclear Medicine 2012 Information

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

In vivo imaging of astrocytosis in Alzheimer’s disease: an 11C-L-deuteriodeprenyl and PIB PET study

Statistical parametric maps of 18F-FDG PET and 3-D autoradiography in the rat brain: a cross-validation study